Loading patent…
AssigneeIndustry-Academic Cooperation Foundation, Yonsei University
InventorsBeom Seok Kim, Chui Hoon Kim, Jong Jin Yoon
Estimating the term…
The present disclosure relates to a pharmaceutical composition for preventing or treating statin-induced adverse effects or a pharmaceutical composition for co-administration with statin, the pharmaceutical composition containing, as an active ingredient, at least one selected from the group consisting of an isoprenoid-based compound, zaragozic acid, terbinafine, and ketoconazole. The pharmaceutical composition according to the present disclosure may prevent and/or treat adverse statin effects that can be induced by statin, that is, can be induced at any time by oxisterols present at abnormal levels in the body. The pharmaceutical composition can not only treat but also prevent the adverse effects of various statin therapeutics whose use has recently increased rapidly, and thus it is expected that the pharmaceutical composition can be widely used for various diseases and the utilization thereof can further be increased.
A method for preventing or treating statin-induced adverse drug reactions, the method comprising administering to a subject in need thereof a pharmaceutically effective amount of an isoprenoid-based compound, wherein the isoprenoid-based compound is any one or more selected from the group consisting of farnesyl pyrophosphate, mevalonate, isopentenyl pyrophosphate, and geranylgeranyl pyrophosphate.
Dependencies are inferred from the claim text.